Evidence map›Paper›PMID 39221276›Full record

ArticlePeerJ2024

Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines.

Matthew E Berginski, Madison R Jenner, Chinmaya U Joisa, Gabriela Herrera Loeza, Brian T Golitz, Matthew B Lipner, Jack R Leary, Naim Rashid, Gary L Johnson, Jen Jen Yeh and 1 more

Abstract read
In one paragraph

Article in PeerJ, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matthew E Berginski *Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Madison R Jenner *Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Chinmaya U JoisaJoint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, United States of America.
Gabriela Herrera LoezaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Brian T GolitzEshelman Institute for Innovation, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Matthew B LipnerDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Jack R LearyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Naim RashidLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Gary L JohnsonDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Jen Jen YehDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.
Shawn M GomezDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.

Funding

Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
SToP Cancer SPORE: Developmental Research ProgramP50CA257911 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jen Jen Yeh · 2022 to 2026
$12.9M
DEVELOPMENT OF HUMAN INTESTINAL SIMULACRAR01DK109559 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ALLBRITTON, NANCY L., BULTMAN, SCOTT J · 2015 to 2019
$5.2M
CANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0M
Integrating tumor and stroma to understand and predict treatment responseU01CA274298 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Naim Ur Rashid, Susan Tsai · 2022 to 2026
$4.7M
Tumor Subtypes and Therapy Response in Pancreatic CancerR01CA199064 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TSAI, SUSAN, YEH, JEN JEN · 2016 to 2021
$4.4M
MICROFABRICATED INSTRUMENTATION TO MEASURE SPHINGOLIPID SIGNALING IN HUMAN ACUTE MYELOID LEUKEMIAR01CA233811 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ALLBRITTON, NANCY L., ARMISTEAD, PAUL MICHAEL · 2019 to 2023
$3.1M
Predictive Modeling of the EGFR-MAPK pathway for Triple Negative Breast Cancer PatientsU01CA238475 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ELSTON, TIMOTHY C, PEROU, CHARLES M · 2019 to 2023
$3.0M
The adaptive kinome in pancreatic cancerR01CA193650 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L., YEH, JEN JEN · 2015 to 2019
$2.9M
Targeted EGFR for basal subtype pancreatic cancerR01CA288145 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARY L. JOHNSON, Jen Jen Yeh · 2024 to 2026
$1.9M
NCI NIH HHS P50 CA257911NCI NIH HHS R01 CA193650NCI NIH HHS R01 CA199064NCI NIH HHS R01 CA233811NCI NIH HHS R01 CA288145NCI NIH HHS T32 CA071341NCI NIH HHS U01 CA238475NCI NIH HHS U01 CA274298NIDDK NIH HHS R01 DK109559NIDDK NIH HHS U24 DK116204
6 · The paper itself

Abstract

Numerous aspects of cellular signaling are regulated by the kinome-the network of over 500 protein kinases that guides and modulates information transfer throughout the cell. The key role played by both individual kinases and assemblies of kinases organized into functional subnetworks leads to kinome dysregulation driving many diseases, particularly cancer. In the case of pancreatic ductal adenocarcinoma (PDAC), a variety of kinases and associated signaling pathways have been identified for their key role in the establishment of disease as well as its progression. However, the identification of additional relevant therapeutic targets has been slow and is further confounded by interactions between the tumor and the surrounding tumor microenvironment. In this work, we attempt to link the state of the human kinome, or kinotype, with cell viability in treated, patient-derived PDAC tumor and cancer-associated fibroblast cell lines. We applied classification models to independent kinome perturbation and kinase inhibitor cell screen data, and found that the inferred kinotype of a cell has a significant and predictive relationship with cell viability. We further find that models are able to identify a set of kinases whose behavior in response to perturbation drive the majority of viability responses in these cell lines, including the understudied kinases CSNK2A1/3, CAMKK2, and PIP4K2C. We next utilized these models to predict the response of new, clinical kinase inhibitors that were not present in the initial dataset for model devlopment and conducted a validation screen that confirmed the accuracy of the models. These results suggest that characterizing the perturbed state of the human protein kinome provides significant opportunity for better understanding of signaling behavior and downstream cell phenotypes, as well as providing insight into the broader design of potential therapeutic strategies for PDAC.

Indexed as

Cancer-Associated FibroblastsCarcinoma, Pancreatic DuctalCell SurvivalPancreatic NeoplasmsProtein KinasesCell Line, TumorHumansProtein Kinase InhibitorsSignal TransductionTumor MicroenvironmentProtein Kinase InhibitorsProtein KinasesCancerCell signalingDrug responseDrug sensitivityKinase inhibitor treatmentMachine learningPancreatic cancerPredictive modelingTumor microenvironment

Identifiers

PMID39221276
PMCPMC11365483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.